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Editorial on the Research Topic
Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents
Protracted bacterial bronchitis (PBB) chronic suppurative lung disease (CSLD) and bronchiecta-
sis unrelated to cystic fibrosis (CF) are commonly seen in pediatric specialist respiratory clinics 
(1–3). Chronic wet cough is common to these conditions and many groups (4, 5) have demonstrated 
infection and intense inflammation in the lower airways of these children. The importance of these 
conditions includes:
 a. These conditions cause respiratory morbidity in developed and developing countries, with 
some affluent countries reporting childhood fatalities (6). In many centers, these conditions are 
increasingly diagnosed (7–9) for a variety of reasons, including improved recognition.
 b. These conditions can be effectively treated leading to improved quality of life (Quell), and clinical 
outcomes, through reducing both short- and long-term morbidity (1, 10). The longer the chronic 
wet cough duration when first diagnosed, the worse the radiographic scores in children (4) and 
adults (11). In a study involving adult-diagnosed broncheictasis, those with chronic cough since 
childhood had significantly worse disease compared to those without childhood symptoms (e.g., 
more exacerbations, lower lung function) (11).
 c. When not optimally managed, accelerated lung function decline and premature death may occur 
(6, 12, 13). Thus, pediatricians have a crucial role in the early detection and optimal management 
of these conditions.
 d. There is increasing evidence that intensive treatment of children who either have CSLD, or who 
are at risk of developing severe CSLD, prevents poor lung function in adulthood (14, 15). Cohort 
data found that, ~80% newly diagnosed adults with broncheictasis were symptomatic since child-
hood, and duration of chronic cough is related (r = −0.51, p < 0.001 in non-smokers) to lung 
function at diagnosis (11) Thus, arguably some of the severe end of this spectrum of illness is 
preventable or modifiable if treated early (16).
Despite the above, children and adolescents with these conditions receive disproportionately 
fewer resources (clinical and research), when compared with other chronic lung diseases. Indeed, 
bronchiectasis is regarded by the European Respiratory Society as one of the most neglected lung 
disease (17). Thus, Frontiers in Pediatrics has a dedicated research topic (edited by Santamaria and 
Chang). The eight mini reviews in this series aim to summarize current knowledge, predominantly 
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for clinicians. The articles addressed various aspects, including 
definitions (Redding and Carter, Ishak and Everard), epidemiol-
ogy and etiological contributions (McCallum and Binks), one 
of the major causes [primary ciliary dyskinesia (PCD) (Mirra 
et  al.)], impact on QoL (Nathan et  al.), and immunology and 
microbiology (Pizzutto et  al.). On the management arm, the 
articles on the airway clearance (Lee et al.) and prevention and 
treatment of exacerbations (O’Grady and Grimwood) provide 
further in-depth insights in addition to recent reviews (8, 18).
There remains a lack of complete agreement on the definitions 
of PBB, CSLD, and bronchiectasis, all with chronic endobronchial 
suppuration. In older literature, as highlighted by Redding and 
Carter, common suppurative lung conditions include bronchi-
ectasis, empyema, lung abscess, and necrotizing pneumonia. In 
our current era, the latter three are usually considered different 
entities. Until recently, bronchiectasis was the most commonly 
recognized form of lung suppuration in children. However, PBB, 
now recognized as a distinct pediatric condition (19), is more 
common than bronchiectasis (Redding and Carter).
In the modern era, the global burden of childhood CSLD and 
bronchiectasis is still poorly addressed. McCallum and Binks 
focused on the epidemiology of CSLD and bronchiectasis in 
children and adolescents. The review provided in-depth data 
on the prevalence of CSLD and bronchiectasis, finding the wide 
variability among countries, with peaks among socially disad-
vantaged indigenous populations of New Zealand, Australia, 
Alaska, and Canada, and lower prevalence in Europe (McCallum 
and Binks). While CSLD and bronchiectasis are more common 
in low- and middle-income countries, it is not uncommon as 
generally perceived in high income countries (2, 20) where many 
centers have hundreds of patients with bronchiectasis. Indeed, it 
is often unappreciated that worldwide, bronchiectasis unrelated 
to CF is far more common than CF.
Chronic suppurative lung disease and bronchiectasis are 
associated with several underlying conditions (e.g., PCD, CF, 
immunodeficiency, post-infectious pneumonia) that may share 
common clinical features (21) although the prevalence of the 
common clinical symptoms and signs vary among studies 
(McCallum and Binks). The main reason for this is likely related 
to severity when assessed and the underlying cause of the CSLD/
bronchiectasis. Nevertheless in most settings, it is likely that PCD 
is an under diagnosed cause of bronchiectasis. This and recent 
advances in this field in the diagnosis were highlighted by Mirra 
et al.. While genetic testing for PCD is far from optimum at this 
point, undoubtedly this field will progress.
There is little doubt that CSLD and bronchiectasis are an 
important cause of respiratory morbidity and reduced QoL 
(Nathan et al.). In affected children and adolescents, a long-term 
follow-up is mandatory, in order to monitor the progression 
of lung impairment. Indeed, an often unmet need in children 
with CSLD and bronchiectasis is a more global approach to the 
disease, which would hopefully take into account also other 
relevant issues that are often neglected such as growth, nutrition, 
and psychological aspects. Considerable stress, anxiety, and 
depression have been reported in primary caregivers who look 
after these patients, and economic costs due to the frequent need 
for health care resources utilization are increasingly appreciated. 
Nathan et al. reviewed studies on the impact on QoL related to 
interventions, exacerbations, hospitalizations, antibiotic require-
ment, and health promotion strategies.
Ishak and Everard outlined several old studies linking chronic 
wet cough to bronchiectasis and pre-bronchiectasis states. They 
also described the importance of eliminating on-going lower 
airway infection and inflammation. Different approaches to 
the definition of PBB was raised (Ishak and Everard), although 
a recent approach (1) and consensus on PBB was achieved by 
the American College of Chest Physicians (22) and also by the 
European Respiratory Society.
Dysregulated host immune response and persistent microbial 
infection are the key components resulting in the development 
of bronchiectasis but its pathophysiology remains poorly defined 
(8). Pizzutto et al. reviewed immunological concepts, highlighting 
the importance of the various components of the host response, 
and the roles of important pathogens focusing on the children 
with no known underlying disorder. They also explored the 
challenges and limitations in identifying the causative pathogens 
and described the scarce data on viruses and new findings on the 
microbiome (Pizzutto et al.).
On the management front, O’Grady and Grimwood high-
lighted the importance of preventing exacerbation and reduction 
of its severity as goals in the management. Achieving this main-
tains lung health and enhances QoL (O’Grady and Grimwood). 
One of the most important intervention options to achieve this 
is utilizing airway-clearance techniques (ACT) (18), reviewed 
by Lee et al. In the consideration of the large patient variability 
(e.g. severity of bronchiectasis, age, preference, ability, etc.) plus 
the many available types of ACT and aids (Lee et al.), it is in the 
child’s best interest that specialized chest physiotherapists’ regular 
review occurs as part of the patient’s management plan. Lee et al. 
provided an overview of these various techniques, a guide to age-
appropriate ACT, as no single superior technique.
Some statements within the articles in this research topic 
are controversial in a field that is now advancing faster than it 
has ever been, albeit still relatively slowly. Although other mini 
reviews of childhood CSLD and bronchiectasis could have been 
included, we hope that this series of articles enhance clinical and 
research interest and awareness in the field of pediatric CSLD and 
bronchiectasis. In doing so, health practitioners who see children 
may improve the lives of many through the early detection, 
treatment, and consequently likely reducing the long-term detri-
mental effects of CSLD and bronchiectasis. Large-scale research 
in this field is still scarce. Extrapolation of therapeutic concepts 
from the adult studies may not be justified in view of the wide 
spectrum of the disease.
aUtHor CoNtriBUtioNS
All authors listed have made substantial, direct, and intellectual 
contribution to the work and approved it for publication.
FUNdiNG
AC is funded by an Australian National Health and Medical 
Research Council (NHMRC) Practitioner Fellowship (1058213).
3Eg et al. Pediatric CSLD and Bronchiectasis
Frontiers in Pediatrics | www.frontiersin.org September 2017 | Volume 5 | Article 196
rEFErENCES
1. Chang AB, Upham JW, Masters IB, Redding GJ, Gibson PG, Marchant JM, 
et al. State of the art. Protracted bacterial bronchitis: the last decade and the 
road ahead. Pediatr Pulmonol (2016) 51(3):225–42. doi:10.1002/ppul.23351 
2. Santamaria F, Montella S, Pifferi M, Ragazzo V, De SS, De PN, et  al. A 
descriptive study of non-cystic fibrosis bronchiectasis in a pediatric pop-
ulation from central and southern Italy. Respiration (2009) 77(2):160–5. 
doi:10.1159/000137510 
3. Chang AB, Oppenheimer JJ, Weinberger MM, Weir KA, Rubin BK, Irwin RS. 
Use of management pathways or algorithms in children with chronic 
cough: systematic reviews. Chest (2016) 149(1):106–19. doi:10.1378/chest. 
15-1403 
4. Douros K, Alexopoulou E, Nicopoulou A, Anthracopoulos MB, Fretzayas 
A, Yiallouros P, et  al. Bronchoscopic and high resolution CT findings in 
children with chronic wet cough. Chest (2011) 140:317–23. doi:10.1378/
chest.10-3050 
5. Chang AB, Oppenheimer JJ, Weinberger MM, Rubin BK, Irwin RS. Children 
with chronic wet or productive cough -treatment and investigations: a system-
atic review. Chest (2016) 149(1):120–42. doi:10.1378/chest.15-2065 
6. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and 
Wales. Respir Med (2010) 104(7):981–5. doi:10.1016/j.rmed.2010.02.022 
7. Bahceci S, Karaman S, Nacaroglu HT, Yazici S, Girit S, Unsal-Karkiner S, et al. 
Changing epidemiology of non-cystic fibrosis bronchiectasis. Turk J Pediatr 
(2016) 58(1):19–26. doi:10.24953/turkjped.2016.01.003 
8. Goyal V, Grimwood K, Masters IB, Marchant JM, Chang AB. State of the art: 
pediatric bronchiectasis. Pediatr Pulmonol (2016) 51(5):450–69. doi:10.1002/
ppul.23380 
9. Altenburg J, Wortel K, van der Werf TS, Boersma WG. Non-cystic fibrosis 
bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by 
data from a Dutch Teaching Hospital. Neth J Med (2015) 73(4):147–54. 
10. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in 
pediatric non-CF bronchiectasis – what influences lung function stability? 
Chest (2010) 138(1):158–64. doi:10.1378/chest.09-2932 
11. King PT, Holdsworth SR, Farmer M, Freezer N, Villanueva E, Holmes PW. 
Phenotypes of adult bronchiectasis: onset of productive cough in childhood 
and adulthood. COPD (2009) 6(2):130–6. doi:10.1080/15412550902766934 
12. Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, et al. Analysis of the 
factors related to mortality in patients with bronchiectasis. Respir Med (2007) 
101(7):1390–7. doi:10.1016/j.rmed.2007.02.002 
13. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, 
et al. Mortality in bronchiectasis: a long-term study assessing the factors influ-
encing survival. Eur Respir J (2009) 34:843–9. doi:10.1183/09031936.00003709 
14. Bastardo CM, Sonnappa S, Stanojevic S, Navarro A, Lopez PM, Jaffe A, et al. 
Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung 
function. Thorax (2009) 64(3):246–51. doi:10.1136/thx.2008.100958 
15. Haidopoulou K, Calder A, Jones A, Jaffe A, Sonnappa S. Bronchiectasis second-
ary to primary immunodeficiency in children: longitudinal changes in structure 
and function. Pediatr Pulmonol (2009) 44(7):669–75. doi:10.1002/ppul.21036 
16. Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic sup-
purative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev (2011) 
12(2):97–103. doi:10.1016/j.prrv.2010.10.008 
17. ERS. Bronchiectasis. (Vol. 15). Sheffield: European Lung White Book (2014). 
p. 176–83.
18. Wurzel DF, Chang AB. An update on pediatric bronchiectasis. Expert Rev 
Respir Med (2017) 11(7):517–32. doi:10.1080/17476348.2017.1335197 
19. Chang AB, Grimwood K, Gibson PG, Upham JW. PBB: definition, mecha-
nisms, and treatment. Lancet Respir Med (2015) 3(10):743–4. doi:10.1016/
S2213-2600(15)00243-X 
20. Kapur N, Grimwood K, Masters IB, Morris PS, Chang AB. Lower airway 
microbiology and cellularity in children with newly diagnosed non-CF 
bronchiectasis. Pediatr Pulmonol (2012) 47(3):300–7. doi:10.1002/ppul.21550 
21. Montella S, Corcione A, Santamaria F. Recurrent pneumonia in children: 
a reasoned diagnostic approach and a single centre experience. Int J Mol Sci 
(2017) 18(2):E296. doi:10.3390/ijms18020296 
22. Chang AB, Oppenheimer JJ, Weinberger MM, Weir KA, Rubin BK, Irwin RS. 
Management of children with chronic wet cough and protracted bacterial 
bronchitis: CHEST Guideline and Expert Panel Report. Chest (2017) 
151(4):884–90. doi:10.1016/j.chest.2017.01.025 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Eg, Mirra, Chang and Santamaria. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
